secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2025-04-21T23:59:59+00:00
Accession:  0001846253-25-000034
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb appoints two new independent directors; Sarah Boyce resigns
------------------------------------------------------------------

- Sarah Boyce resigned from Board and all committees effective April 18; no disagreement with company.
- Steven C. Crouse and Philip J. Gotwals appointed as Class II directors, terms expiring at 2027 annual meeting.
- Crouse (Bio-Techne SVP) and Gotwals (former Novartis BD head) bring life sciences and biopharma expertise.
- Each received initial equity grants: RSUs for 40,000 shares and options for 80,000 shares.
- Board size increased from six to seven; new directors deemed independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000184625325000034/0001846253-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000184625325000034/oabi-20250418.htm
  HTML page:      https://secwatch.observer/filing/0001846253-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer